{
    "organizations": [],
    "uuid": "b46a173dd195b6ecdcf2fce6fd50714d1dc90546",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alkermes-announces-fda-acceptance/brief-alkermes-announces-fda-acceptance-for-review-of-new-drug-application-for-alks-5461-idUSASC09VW3",
    "ord_in_thread": 0,
    "title": "BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16, 2018 / 10:53 AM / Updated 9 minutes ago BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461 Reuters Staff 1 Min Read \nApril 16 (Reuters) - Alkermes Plc: \n* ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER \n* ALKERMES PLC - FDA ACTION EXPECTED BY JAN. 31, 2019 \n* ALKERMES - ALKS 5461 NDA FILING BASED ON RESULTS FROM A CLINICAL EFFICACY AND SAFETY PACKAGE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-16T13:53:00.000+03:00",
    "crawled": "2018-04-16T14:06:38.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "announces",
        "fda",
        "acceptance",
        "review",
        "new",
        "drug",
        "application",
        "alks",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "alkermes",
        "plc",
        "alkermes",
        "announces",
        "fda",
        "acceptance",
        "review",
        "new",
        "drug",
        "application",
        "alks",
        "adjunctive",
        "treatment",
        "major",
        "depressive",
        "disorder",
        "alkermes",
        "plc",
        "fda",
        "action",
        "expected",
        "alkermes",
        "alks",
        "nda",
        "filing",
        "based",
        "result",
        "clinical",
        "efficacy",
        "safety",
        "package",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}